Cargando…

A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions

PURPOSE: Pemetrexed is a widely used cytostatic agent with an established exposure–response relationship. Although dosing is based on body surface area (BSA), large interindividual variability in pemetrexed plasma concentrations is observed. Therapeutic drug monitoring (TDM) can be a feasible strate...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Rouw, Nikki, Visser, Sabine, Koolen, Stijn L. W., Aerts, Joachim G. J. V., van den Heuvel, Michel M., Derijks, Hieronymus J., Burger, David M., ter Heine, Rob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994532/ https://www.ncbi.nlm.nih.gov/pubmed/31853639 http://dx.doi.org/10.1007/s00280-019-04006-x

Ejemplares similares

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
por: de Rouw, Nikki, et al.
Publicado: (2021)

The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
por: de Rouw, Nikki, et al.
Publicado: (2022)

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
por: de Rouw, Nikki, et al.
Publicado: (2022)

Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
por: van Ewijk‐Beneken Kolmer, Eleonora W. J., et al.
Publicado: (2021)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
por: van der Galiën, Ruben, et al.
Publicado: (2018)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles
por: Visser, S., et al.
Publicado: (2019)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
por: ter Heine, Rob, et al.
Publicado: (2023)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
por: Cao, Peng, et al.
Publicado: (2022)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair
por: Bulgar, A D, et al.
Publicado: (2012)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017)

Pemetrexed for epithelioid haemangioendothelioma of the pleura
por: Kanemura, Shingo, et al.
Publicado: (2016)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells
por: Wouters, An, et al.
Publicado: (2010)

Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells
por: Dorn, Patrick, et al.
Publicado: (2016)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Eyelid and feet edema induced by pemetrexed
por: Kastalli, Sarrah, et al.
Publicado: (2016)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

Edema of the face and extremities secondary to pemetrexed
por: Doyle, Thomas, et al.
Publicado: (2023)

Multiobjective Resource-Constrained Project Scheduling with a Time-Varying Number of Tasks
por: Abello, Manuel Blanco, et al.
Publicado: (2014)

Joint optimization of green vehicle scheduling and routing problem with time-varying speeds
por: Zhang, Dezhi, et al.
Publicado: (2018)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
por: Michalak, Olga, et al.
Publicado: (2015)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
por: Agema, Bram C., et al.
Publicado: (2020)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ff9r8eofdeq4k1id782coj7f5n